Covidien bulks up share value with meaty $2bn share buy-back
This article was originally published in Clinica
Executive Summary
Covidien's board has approved a share repurchase programme worth an unexpectedly substantial $2bn. The company intends to purchase this stock "from time to time, based on market conditions".